Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028602 | 0.88 | ADA (0.61) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL136037 | 0.88 | ADA (0.61) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL772296 | 0.87 | ADA (0.63) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL5064838 | 0.87 | ADA (0.60) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL3345754 | 0.86 | ADA (0.60) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL288325 | 0.86 | ADA (0.58) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL8000695 | 0.86 | ADA (0.58) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL4830369 | 0.83 | ADORA3 (0.42) | ADAADORA3 | |
| SCHEMBL6297520 | 0.83 | ADA (0.55) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL13727118 | 0.83 | ADA (0.55) | ADAALDH1A1TP53HTTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1809 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209035-A1 | POLYNUCLEOTIDES CAPABLE OF ENHANCED PROTEIN EXPRESSION AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2024-06-27 | — | — | US | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4323382-A1 | POLYNUCLEOTIDES CAPABLE OF ENHANCED PROTEIN EXPRESSION AND USES THEREOF | Biorchestra Co., Ltd. (KR) | 2024-02-21 | — | — | EP | claimed |
| EP-3359670-B2 | METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS | MODERNATX INC (US) | 2024-02-14 | — | — | EP | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| CN-117500822-A | Polynucleotide capable of enhancing protein expression and use thereof | 生物欧赛加有限责任公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2024026490-A1 | POLYNUCLEOTIDES ENCODING LINKED ANTIGENS AND USES THEREOF | SQZ BIOTECHNOLOGIES COMPANY (US) | 2024-02-01 | — | — | WO | claimed |
| EP-4274846-A1 | EXPRESSION CONSTRUCTS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023212618-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20180311343-A1 | MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF | MODERNATX, INC. | 2018-11-01 | — | — | US | claimed |
| EP-3394093-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | claimed |
| US-20180256628-A1 | METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS | ARES CAPITAL CORPORATION, AS AGENT | 2018-09-13 | — | — | US | claimed |
| WO-2018081459-A1 | MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2018-05-03 | — | — | WO | claimed |
| WO-2017120612-A1 | THERAPEUTIC MRNAS ENCODING ANTI CTLA-4 ANTIBODIES | MODERNATX, INC. (US) | 2017-07-13 | — | — | WO | claimed |
| WO-2017112943-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| WO-2017062513-A1 | METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS | MODERNATX, INC. (US) | 2017-04-13 | — | — | WO | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209035-A1 | POLYNUCLEOTIDES CAPABLE OF ENHANCED PROTEIN EXPRESSION AND USES THEREOF | UPF1, PABPC4, NSUN3 | ADA 297/4885ALDH1A1 4781/4885TP53 772/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ADA 29/4885ALDH1A1 2324/4885TP53 411/4885 |
| US-20180311343-A1 | MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF | EIF2AK2, IRF3, STING1 | ADA 230/4885ALDH1A1 4774/4885TP53 161/4885 |
| US-20180256628-A1 | METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS | ADAR, HAVCR2, NSUN2 | ADA 5/4885ALDH1A1 2172/4885TP53 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.